Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 3Terminated 2Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 84INDUSTRY 24NIH 23NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 1Melanoma 1Gastric and Esophagogastric Junction Adenocarcinoma 1

Interventions

Specimen Handling 19Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Vincristine 16Dexamethasone 15Radiotherapy 14Cisplatin 14Radiation 12Etoposide 11Doxorubicin 11Radiotherapy, Intensity-Modulated 10Carboplatin 10durvalumab 9Paclitaxel 9Cytarabine 8Temozolomide 7Rituximab 7Radiotherapy, Conformal 7Prednisone 7Lenalidomide 7Irinotecan 7Gemcitabine 7Fluorouracil 7Docetaxel 7Bortezomib 7Biopsy 7daratumumab 6Platinum 6Leucovorin 6Capecitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Ipilimumab × Clear all
NCT03235245 2025-08-01

EBIN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
271 enrolled
Dermatologic

Melanoma

NCT02785952 2025-05-21

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

SWOG Cancer Research Network

Phase 3 Active not recruiting
275 enrolled 15 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03443856 2024-01-05

VESTIGE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
197 enrolled
Gastrointestinal

Gastric and Esophagogastric Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡